Cargando…

Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women

We hypothesized that soy isoflavones would attenuate the anticipated increase in androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-C, HDL-C, glucose, insulin, uric acid, C-reactive...

Descripción completa

Detalles Bibliográficos
Autores principales: Matvienko, O. A., Alekel, D. L., Bhupathiraju, S. N., Hofmann, H., Ritland, L. M., Reddy, M. B., Van Loan, M. D., Perry, C. D.
Formato: Texto
Lenguaje:English
Publicado: SAGE-Hindawi Access to Research 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010706/
https://www.ncbi.nlm.nih.gov/pubmed/21197412
http://dx.doi.org/10.4061/2011/904878
_version_ 1782194829379239936
author Matvienko, O. A.
Alekel, D. L.
Bhupathiraju, S. N.
Hofmann, H.
Ritland, L. M.
Reddy, M. B.
Van Loan, M. D.
Perry, C. D.
author_facet Matvienko, O. A.
Alekel, D. L.
Bhupathiraju, S. N.
Hofmann, H.
Ritland, L. M.
Reddy, M. B.
Van Loan, M. D.
Perry, C. D.
author_sort Matvienko, O. A.
collection PubMed
description We hypothesized that soy isoflavones would attenuate the anticipated increase in androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-C, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine. We collected data on 224 healthy postmenopausal women at risk for osteoporosis (45.8–65 y, median BMI 24.5) who consumed placebo or soy isoflavones (80 or 120 mg/d) for 36 months and used longitudinal analysis to examine the contribution of isoflavone treatment, androidal fat mass, other biologic factors, and dietary quality to cardiometabolic outcomes. Except for homocysteine, each cardiometabolic outcome model was significant (overall P-values from ≤.0001 to .0028). Androidal fat mass was typically the strongest covariate in each model. Isoflavone treatment did not influence any of the outcomes. Thus, androidal fat mass, but not isoflavonetreatment, is likely to alter the cardiometabolic profile in healthy postmenopausal women.
format Text
id pubmed-3010706
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher SAGE-Hindawi Access to Research
record_format MEDLINE/PubMed
spelling pubmed-30107062010-12-30 Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women Matvienko, O. A. Alekel, D. L. Bhupathiraju, S. N. Hofmann, H. Ritland, L. M. Reddy, M. B. Van Loan, M. D. Perry, C. D. Cardiol Res Pract Research Article We hypothesized that soy isoflavones would attenuate the anticipated increase in androidal fat mass in postmenopausal women during the 36-month treatment, and thereby favorably modify the circulating cardiometabolic risk factors: triacylglycerol, LDL-C, HDL-C, glucose, insulin, uric acid, C-reactive protein, fibrinogen, and homocysteine. We collected data on 224 healthy postmenopausal women at risk for osteoporosis (45.8–65 y, median BMI 24.5) who consumed placebo or soy isoflavones (80 or 120 mg/d) for 36 months and used longitudinal analysis to examine the contribution of isoflavone treatment, androidal fat mass, other biologic factors, and dietary quality to cardiometabolic outcomes. Except for homocysteine, each cardiometabolic outcome model was significant (overall P-values from ≤.0001 to .0028). Androidal fat mass was typically the strongest covariate in each model. Isoflavone treatment did not influence any of the outcomes. Thus, androidal fat mass, but not isoflavonetreatment, is likely to alter the cardiometabolic profile in healthy postmenopausal women. SAGE-Hindawi Access to Research 2010-12-19 /pmc/articles/PMC3010706/ /pubmed/21197412 http://dx.doi.org/10.4061/2011/904878 Text en Copyright © 2011 O. A. Matvienko et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Matvienko, O. A.
Alekel, D. L.
Bhupathiraju, S. N.
Hofmann, H.
Ritland, L. M.
Reddy, M. B.
Van Loan, M. D.
Perry, C. D.
Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women
title Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women
title_full Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women
title_fullStr Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women
title_full_unstemmed Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women
title_short Androidal Fat Dominates in Predicting Cardiometabolic Risk in Postmenopausal Women
title_sort androidal fat dominates in predicting cardiometabolic risk in postmenopausal women
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010706/
https://www.ncbi.nlm.nih.gov/pubmed/21197412
http://dx.doi.org/10.4061/2011/904878
work_keys_str_mv AT matvienkooa androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen
AT alekeldl androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen
AT bhupathirajusn androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen
AT hofmannh androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen
AT ritlandlm androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen
AT reddymb androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen
AT vanloanmd androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen
AT perrycd androidalfatdominatesinpredictingcardiometabolicriskinpostmenopausalwomen